Hermetica Superfood Encyclopedia
The Short Answer
Grifola frondosa contains a proteoglycan complex called D-fraction, a (1→3, 1→6)-β-D-glucan that activates innate and adaptive immune effector cells by binding pattern recognition receptors including Dectin-1 and complement receptor 3 on macrophages, dendritic cells, and natural killer cells. In preclinical tumor models and preliminary human adjunct oncology trials, D-fraction and its purified derivative MD-fraction have demonstrated tumor growth inhibition and immunostimulatory activity, though large-scale randomized controlled trial evidence in humans remains limited.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary Keywordmaitake mushroom benefits
Maitake — botanical close-up
Health Benefits
**Immunomodulation via β-Glucan Activation**
The D-fraction and MD-fraction proteoglycan complexes bind Dectin-1 and complement receptor 3 (CR3) on macrophages and dendritic cells, triggering cytokine cascades including TNF-α, IL-1β, and IL-12 that prime both innate and adaptive immune responses.
**Antitumor and Adjunct Oncology Support**
Grifolan and D-fraction have demonstrated dose-dependent tumor growth inhibition in sarcoma and Lewis lung carcinoma mouse models; preliminary human studies suggest improved quality-of-life metrics and immunological parameters when used adjunctively with conventional chemotherapy.
**Blood Glucose Regulation**: Polysaccharide fractions from G
frondosa have shown hypoglycemic effects in high-fat diet combined with streptozotocin (HFD+STZ)-induced hyperglycemic mouse models, with proposed mechanisms involving improved insulin sensitivity and inhibition of intestinal glucose absorption.
**Antioxidant Activity**
The fruiting body yields a total phenolic content of 38.83 mg gallic acid equivalents per gram and a total flavonoid content of 5.73 mg quercetin equivalents per gram, with individual phenolics including gallic acid (223.03 mg/kg dry extract) contributing to free radical scavenging and reduction of oxidative stress markers.
**Antifungal and Antimicrobial Properties**
The furanone compound grifolaone A, first identified in G. frondosa, exhibits specific antifungal activity, while the phenolic fraction's hydroxyl groups interact with microbial amino groups to exert antimicrobial effects that may also reduce volatile basic nitrogen formation.
**Antiviral Potential**: Bioactive fractions from G
frondosa have demonstrated anti-Enterovirus 71 (anti-EV71) activity in cell culture models, suggesting nucleocapsid-level or entry-level inhibition, though in vivo and clinical confirmation is still pending.
**Glycoprotein-Mediated Immunomodulation**
The characterized glycoprotein GFG-3a (molecular weight 88.01 kDa), composed of arabinose, fructose, mannose, and glucose in defined molar ratios, exhibits antitumor and antioxidant activities distinct from the polysaccharide-only fractions, suggesting multiple parallel immunomodulatory pathways.
Origin & History
Natural habitat
Grifola frondosa is a polypore mushroom native to temperate hardwood forests of northeastern Japan, China, and eastern North America, where it grows at the base of oak, elm, and maple trees during late summer and autumn. It has been cultivated commercially in Japan since the 1980s using sawdust-based substrate blocks under controlled humidity and temperature conditions, with fruiting body yields dependent heavily on strain selection and substrate composition. Wild harvesting remains culturally significant in rural Japan, where the mushroom's rarity and large size—clusters can exceed 50 kg—historically made discovery a celebrated event.
“In Japan, Grifola frondosa has been prized for centuries under the name 'maitake' (舞茸), meaning 'dancing mushroom,' a name attributed either to the joyful dance performed by those who discovered the rare and valuable fungus in the wild or to the mushroom's overlapping, fan-like fronds that resemble dancing figures. Historical Japanese texts and materia medica reference maitake as a tonic food used to promote longevity, strengthen the body, and support vitality, positioning it alongside other revered medicinal fungi such as reishi (Ganoderma lucidum) and shiitake (Lentinula edodes) in traditional kampo-adjacent health practices. In traditional Chinese medicine, the mushroom was categorized as a food that nourishes the spleen and stomach, calms the nerves, and was occasionally referenced in regional herbals for its general strengthening properties, though it was less prominent than other medicinal fungi in classical Chinese formularies. Commercial cultivation breakthrough in Japan during the 1980s transformed maitake from a rare forest delicacy into a widely accessible food and supplement ingredient, catalyzing the modern scientific investigation of its D-fraction and MD-fraction bioactive components beginning in the late 1980s and 1990s.”Traditional Medicine
Scientific Research
The evidence base for G. frondosa consists predominantly of in vitro cell culture studies, rodent tumor model experiments, and a small number of phase I/II human pilot studies, placing the overall evidence quality at a preclinical-to-early-clinical level. Rodent studies using sarcoma-180 and Lewis lung carcinoma implantation models have demonstrated statistically significant tumor weight reduction with D-fraction administration, with some studies reporting inhibition rates exceeding 80% compared to vehicle controls, but direct translation to human oncology outcomes has not been validated in large randomized controlled trials. A small number of open-label and pilot human studies have evaluated D-fraction or MD-fraction as adjuncts to chemotherapy in breast, lung, and liver cancer patients, reporting improved natural killer cell activity and patient-reported symptom scores, but these studies are limited by small sample sizes (typically fewer than 50 participants), lack of placebo controls, and heterogeneous patient populations. Comprehensive systematic reviews and meta-analyses covering rigorously controlled human clinical trials have not yet been published, and regulatory bodies such as the FDA and EMA have not approved G. frondosa extracts as pharmaceutical agents, classifying commercial preparations as dietary supplements.
Preparation & Dosage
Traditional preparation
**Dried Whole Fruiting Body Powder**
000 mg per day in divided doses; the least standardized form but retains the full complement of polysaccharides, proteins, and phenolics
1,500–3,.
**Hot Water Extract (Standardized Polysaccharide)**
100–300 mg per day standardized to ≥20–30% β-glucan content; the most common commercial supplement form used in immune-support products
**D-Fraction Liquid Extract**
0 mg/kg body weight per day as evaluated in pilot oncology studies; formulated as a concentrated proteoglycan solution typically taken sublingually or mixed into beverages
0.1–1..
**MD-Fraction (Purified D-Fraction)**
35–150 mg daily depending on indication and patient weight
The enhanced pharmaceutical-grade preparation used in Japanese clinical research settings, dosed at .
**Traditional Culinary Preparation**
Fresh or dried mushroom steeped as a tea or cooked in soups and broths; water-soluble polysaccharides are partially extracted through cooking, though bioavailability relative to concentrated extracts is lower.
**Mycelium-Based Preparations**
Cultured mycelium biomass standardized similarly to fruiting body extracts; note that mycelium products may contain substrate material and variable β-glucan concentrations compared to fruiting body preparations.
**Timing**
Best taken with or shortly before meals to optimize gastrointestinal absorption; no established circadian timing preference has been validated in clinical trials.
Nutritional Profile
The fruiting body of G. frondosa is nutritionally dense on a dry weight basis: crude protein content ranges from 17.8% to 28.4% depending on cultivation substrate and strain, making it a meaningful non-animal protein source. Total carbohydrate content is substantial, with water-soluble polysaccharides comprising approximately 3.8% dry weight, of which 13.2% is the bioactive (1→3, 1→6)-β-D-glucan fraction. Ergosterol (provitamin D2) is a key sterol present in the fungal cell membrane and is converted to vitamin D2 upon ultraviolet light exposure, as is common across edible mushrooms. Phenolic content is notable at 38.83 mg GAE/g dry weight, with gallic acid (223.03 mg/kg dry extract) as the dominant individual phenolic, followed by vanillic acid (25.26 mg/kg) and caffeic acid (9.26 mg/kg). The mushroom also provides dietary fiber from indigestible polysaccharide fractions, B vitamins (particularly niacin and riboflavin), potassium, copper, and selenium in concentrations relevant to daily micronutrient intake. Bioavailability of β-glucans is influenced by molecular weight and branching structure: higher-molecular-weight fractions such as Grifolan-7N (1200 kDa) may resist gastrointestinal degradation better than lower-weight variants, but systemic absorption mechanisms (including intestinal receptor-mediated endocytosis) remain under investigation.
How It Works
Mechanism of Action
The primary immunomodulatory mechanism of G. frondosa centers on its high-molecular-weight β-glucan fractions—particularly D-fraction and Grifolan (GRN, ~500 kDa)—which bind the C-type lectin receptor Dectin-1 and complement receptor 3 (CR3/Mac-1) on macrophages, dendritic cells, and natural killer cells, initiating intracellular signaling through Syk kinase and NF-κB pathways that upregulate pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12) and stimulate oxidative burst activity. Grifolan-7N (1200 kDa), a (1→3)-linked β-D-glucan extracted from the fruiting body via hot sodium hydroxide, forms gel-like structures at physiological concentrations that may enhance mucosal immune interactions and slow enzymatic degradation, prolonging receptor engagement. Phenolic constituents such as gallic acid interact with reactive oxygen species directly through electron donation and may modulate Nrf2/ARE signaling to upregulate endogenous antioxidant enzymes including superoxide dismutase and catalase. The structure-to-bioactivity relationship remains incompletely characterized, and elucidating the precise receptor binding kinetics, downstream transcriptomic changes, and differential contributions of proteoglycan versus free polysaccharide fractions requires further investigation.
Clinical Evidence
The most clinically relevant human data for G. frondosa involve its use as an immunological adjunct in oncology settings, where pilot studies have assessed changes in peripheral natural killer cell activity, T-lymphocyte counts, and quality-of-life scores in cancer patients receiving D-fraction or MD-fraction alongside standard chemotherapy regimens. One notable open-label pilot study in postmenopausal breast cancer patients evaluated immunological parameters following oral MD-fraction administration at doses of 0.1–1.0 mg/kg/day, observing dose-dependent immunological stimulation—defined by increased NK cell cytotoxicity—in the majority of participants, though the absence of a placebo arm limits causal interpretation. Hypoglycemic and insulin-sensitizing effects have been explored primarily in animal models (HFD+STZ-induced hyperglycemic mice) with no adequately powered human RCTs confirming glycemic benefit. Confidence in the clinical evidence for any indication remains low to moderate; while preclinical data are consistently favorable, the transition to validated human therapeutic outcomes requires larger, double-blind, placebo-controlled trials with pre-specified endpoints and standardized extract preparations.
Safety & Interactions
Grifola frondosa consumed as a culinary mushroom is generally recognized as safe, and short-term use of standardized extracts in clinical studies has not produced serious adverse events; mild gastrointestinal symptoms such as bloating or loose stools have been occasionally self-reported at higher polysaccharide doses. Due to its immunostimulatory mechanism—upregulating macrophage, NK cell, and T-cell activity—G. frondosa extracts may theoretically antagonize immunosuppressive drugs such as cyclosporine, tacrolimus, mycophenolate mofetil, and corticosteroids used in transplant recipients or autoimmune disease management, and concurrent use warrants medical supervision. Preliminary evidence of hypoglycemic effects in animal models raises the concern of additive blood glucose lowering when combined with insulin, metformin, sulfonylureas, or other antidiabetic agents, necessitating blood glucose monitoring in diabetic patients. Safety data during pregnancy and lactation are absent from the peer-reviewed literature, and supplemental use in these populations cannot be recommended without clinical guidance; no established maximum safe dose has been formally determined for humans through toxicological dose-escalation studies.
Synergy Stack
Hermetica Formulation Heuristic
Featured in
Eternity
Functional mushroom gummies — Lion's Mane, Reishi, Cordyceps, Chaga & Maitake.
Shop Now →
Also Known As
Grifola frondosa (Dicks.) GrayMaitakeDancing MushroomHen of the WoodsSheep's Head Mushroom云蕈 (Yún Zhú)D-fraction mushroom
Frequently Asked Questions
What is maitake D-fraction and what does it do?
Maitake D-fraction is a purified proteoglycan complex extracted from Grifola frondosa fruiting bodies, consisting primarily of (1→3, 1→6)-β-D-glucan chains bound to protein. It exerts immunomodulatory effects by binding the Dectin-1 receptor and complement receptor 3 on macrophages, dendritic cells, and natural killer cells, triggering cytokine release and enhanced immune surveillance. It has been studied as an adjunct to conventional cancer treatments in Japanese clinical settings, where pilot studies reported improvements in NK cell activity and patient quality-of-life scores.
What is the recommended dosage of maitake mushroom extract?
Standard hot-water maitake extracts standardized to 20–30% β-glucan are typically taken at 100–300 mg per day for general immune support. In oncology-focused pilot studies, D-fraction and MD-fraction have been evaluated at doses of 0.1–1.0 mg/kg body weight per day, equating to roughly 7–70 mg for a 70 kg adult depending on indication. Culinary use of dried maitake powder ranges from 1,500–3,000 mg daily, though polysaccharide bioavailability in this unprocessed form is lower than in standardized extracts.
Can maitake mushroom help with blood sugar control?
Preclinical research using high-fat diet combined with streptozotocin (HFD+STZ)-induced hyperglycemic mouse models has shown that G. frondosa polysaccharide fractions can reduce fasting blood glucose and improve insulin sensitivity. The proposed mechanisms include inhibition of intestinal glucose absorption and enhanced peripheral glucose uptake, but these findings have not yet been replicated in adequately powered human randomized controlled trials. Diabetic patients taking blood-sugar-lowering medications should exercise caution and monitor glucose levels if using maitake supplements, due to potential additive hypoglycemic effects.
Is maitake mushroom safe to take, and are there any drug interactions?
Maitake consumed as a food is well-tolerated, and short-term supplemental use in clinical studies has not produced serious adverse effects beyond occasional mild gastrointestinal discomfort at high doses. However, its immunostimulatory mechanism poses a theoretical risk of reducing the effectiveness of immunosuppressive medications such as cyclosporine, tacrolimus, and corticosteroids used in organ transplant recipients or autoimmune conditions. Additive hypoglycemia is also a concern when combined with insulin or oral antidiabetic agents, and safety in pregnancy and lactation has not been established.
How does maitake compare to other medicinal mushrooms like reishi or turkey tail?
Maitake (G. frondosa), reishi (Ganoderma lucidum), and turkey tail (Trametes versicolor) all contain immunomodulatory β-glucan polysaccharides but differ in their specific fractions and secondary bioactive profiles. Turkey tail's PSK and PSP fractions have the most robust human clinical trial data, particularly as adjuncts to chemotherapy in Japan where PSK is approved as a pharmaceutical agent, whereas maitake's D-fraction evidence rests primarily on preclinical models and small pilot human studies. Reishi is distinguished by its triterpenoid content (ganoderic acids) in addition to β-glucans, giving it a broader anti-inflammatory and adaptogenic pharmacological profile, while maitake's phenolic content and unique grifolaone A antifungal compound set it apart at the phytochemical level.
What is the difference between maitake mushroom powder and extract, and which form has better bioavailability?
Maitake extracts, particularly alcohol or hot-water extracts, concentrate the bioactive β-glucans and proteoglycan complexes (D-fraction and MD-fraction) into a more potent form compared to raw powder. Standardized extracts typically deliver higher levels of immunomodulatory compounds per dose and have superior bioavailability due to the extraction process breaking down the fungal cell wall, making polysaccharides more accessible for absorption. Whole mushroom powder contains beneficial compounds but requires higher doses to achieve equivalent bioactivity.
Who would benefit most from taking maitake mushroom supplements—are there specific populations it works best for?
Maitake is particularly beneficial for individuals seeking immune support, those with compromised immune function, and those undergoing wellness protocols that emphasize natural immune modulation through β-glucan activation. It may also appeal to older adults and those managing stress-related immune challenges, as research suggests maitake strengthens both innate and adaptive immune responses via macrophage and dendritic cell activation. People interested in complementary approaches to cellular health and general wellness are common users, though individual responses vary based on baseline immune status and overall health.
How does the scientific evidence for maitake's immune benefits compare to its potential antitumor applications?
Clinical evidence for maitake's immunomodulatory effects is well-established, with documented activation of macrophages, dendritic cells, and cytokine production (TNF-α, IL-1β, IL-12) through Dectin-1 and CR3 receptor binding. Research on antitumor potential is more preliminary and typically involves in vitro or animal studies showing dose-dependent effects of grifolan and D-fraction on cellular responses. While the immune-support evidence is relatively robust, claims regarding direct antitumor applications should be viewed as exploratory, and maitake should not replace conventional oncology treatments.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w maitake-mushroom-grifola-frondosa-dicks-gray curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
